Source: Fortune
Daraxonrasib nearly doubled pancreatic cancer survival to 13.2 months — but the IRA's "Pill Penalty" threatens the system that produced it.
Aller á la Source
Nouvelles connexes
List des news
Source: Fortune
Daraxonrasib nearly doubled pancreatic cancer survival to 13.2 months — but the IRA's "Pill Penalty" threatens the system that produced it.